VG S&P M-Cap 400

Burlington Stores to Release FY2027 Q1 Earnings on May 28 Pre-Market EST, Forecast Revenue USD 2.8 B, EPS USD 1.772

Flex Reports FY2026 Earnings: Revenue Beats Expectations, EPS Misses

Flex Plans to Spin Off Cloud and Power Infrastructure Division by Q1 2027

Juniper Therapeutics CEO Martin Rosenthal Sells 9,500 Shares for $5.34 Million

Flex released FY2026 annual earnings on May 20 Pre-Market EST, actual revenue USD 27.91 B (forecast USD 27.4 B), actual EPS USD 2.33 (forecast USD 2.46)

Zacks Research Raises Woodward's 2026 Q3 EPS Forecast to $2.28

United Therapeutics CFO James Edmonds Sells $5.64M in Stock

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Northern Mutual Wealth Increases Kashi Grocery Stake by Nearly 180x to $1.47B, Zacks Upgrades Rating to Strong Buy

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Valeo Financial Advisors Acquires $571k of Flex Ltd. Stock in Q4

Plancorp Increases Stake in Royal Gold by 69.8% in Q4

Flex Executives Sell Shares

James Edgemond Sells United Therapeutics Stock

Joint Treatment CFO Exercises Stock Options and Sells Shares

United Therapeutics to Present New Data on Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension at ATS

Curtiss-Wright Raises 2026 Full-Year Outlook

Optimi Health

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

VTWV

IVOO

VTWG

IVOV

VIOO

Ivan Illan, Chief Investment Officer at AWAIM, discusses the paradox in the U.S. equity market as of mid-2026, highlighting strong earnings growth in the S&P 500 but elevated valuations. He advocates for a selective approach to U.S. small and mid-cap (SMID) companies, noting significant dispersion within the asset class that presents opportunities for active managers. However, he warns of risks related to debt refinancing and emphasizes the potential for well-positioned firms to gain market share. The manufacturing sector shows signs of recovery, further supporting selective SMID investment.

Forbes

iShares Core S&P Small Cap

Vanguard Russell 2000 Value

Direxion Small Cap Bull 3X

ISHRS Russ 2000 Val

iShares Russell 2000

Vanguard Russell 2000 Growth

SPDR S&P 600 S-Cp Val

VG S-Cp Value

VG S&P M-Cap 400 Val

Avantis Int Small Cap Value

iShares Core S&P Mid Cap

Capital Group U.S. Small and Mid Cap ETF

VG S&P S-Cp 600

VG Mid-Cap Val

ISHRS Russ 2000 Growth

Pro Rsl 2000 Dvd Grw

Vanguard Russell 2000

Avantis U.S. Small Cap Value

VG S-Cp Grw

S&P 500

The SMID Cap Conundrum: Dispersion, Deleveraging And The Selective Opportunity Ahead

MIDE

GRPM

SPMD

The Vanguard S&P Mid-Cap 400 Index Fund ETF Shares (IVOO) offers broad exposure to the Mid Cap Blend segment of the US equity market. Launched in 2010, it has $3.54 billion in assets and a low expense ratio of 0.07%. The ETF has a 12-month dividend yield of 1.21% and is primarily allocated to the Industrials sector. With a year-to-date performance of 12.34% and a one-year increase of 26.94%, IVOO is rated as a Strong Buy by Zacks. It is a suitable option for long-term investors seeking low-cost, transparent investment vehicles.

nasdaq

Xtrackers S&P MidCap 400 ESG ETF

Invesco S&P MidCap 400® GARP ETF

SPDR Portfolio S&P 400 Mid Cap ETF

TechnipFMC

Casey General Stores

United Therap

VG Mid-Cap

Nasdaq

Should Vanguard S&P Mid-Cap 400 Index Fund ETF Shares (IVOO) Be on Your Investing Radar?

MCOW

ITWO

As global markets recover post-U.S.-Iran ceasefire, small-cap stocks like S&P MidCap 400 and Russell 2000 gain traction. Investors are eyeing undervalued small caps with insider buying as indicators of potential value. Notable picks include Eastnine, MedCap, and MCAN Mortgage, each showing strong fundamentals and insider confidence despite some financial challenges. Eastnine reported a turnaround in performance, MedCap's revenue growth is promising, and MCAN Mortgage increased dividends, reflecting optimism. The article highlights 170 undervalued global small caps for investors to consider.

Simplywall

ISHRS S&P M-Cap 400/Barra Growth

NEOS Russell 2000 High Income ETF

Pacer S&P MidCp 400 Qul FCF Arstcrts ETF

Wtree Us M-Cp Fund

Global X Russell 2000 ETF

ProShares Russell 2000 High Income ETF

SPDR S&P 400 Mid Capgrow

SPDR S&P Midcap 400

Global's Top 3 Undervalued Small Caps With Insider Buying To Consider

DTCR

DigitalOcean Holdings will join the S&P MidCap 400 on April 9, 2026, impacting its capital allocation and trading profile. This move may influence perceptions of growth and risk, particularly in relation to AI-driven growth and high debt levels. Analysts project $1.3 billion in revenue and $182 million in earnings by 2028, but caution exists around churn and pricing pressures. The stock's fair value is estimated at $59.58, indicating a potential downside. Investors are encouraged to consider both optimistic and cautious narratives regarding DigitalOcean's future.

Global X Data Center & Dgtl Infrs ETF

American Century Mid Cap Growth Impact ETF

Digitalocean

ISHRS S&P Glb It

Franklin Exponential Data ETF

Pacer Data & Infrastructure Real Estate ETF

iShares US Digital Infrastructure and Real Estate ETF

Global X Cloud Computing ETF

Proshares Big Data Refiners ETF

Does DigitalOcean (DOCN) Entering the S&P MidCap 400 Reframe Its Balance of Growth and Risk?

SOLS

Solstice Advanced Materials (NasdaqGS:SOLS) has been added to the S&P MidCap 400 during the March 2026 quarterly rebalancing, highlighting its growing significance in the AI supply chain. The stock, currently priced at $72.17, has seen a 46.4% year-to-date return, despite a recent 8.1% decline. This inclusion may influence trading volumes and ownership as index funds adjust their holdings. Analysts have set a target price of $83.83, indicating potential undervaluation. Investors are advised to monitor the company's performance and market positioning closely.

Solstice Advanced Materials

ISHRS S&P M-Cap 400/Barra Val

Solstice Joins S&P MidCap 400 As AI Supply Chain Valuation Story Grows

State Street Investment Management forecasts the S&P 500 will return 39% over the next five years, while the S&P Mid-Cap 400 and S&P Small-Cap 600 are expected to return 41% and 42%, respectively. Investors are advised to consider the Vanguard S&P Mid-Cap 400 ETF and the Vanguard S&P Small-Cap 600 ETF for exposure to these indexes. However, concerns are raised about the long-term performance of mid-cap and small-cap funds compared to the S&P 500, which is seen as a more stable investment due to its rebalancing and focus on top-performing stocks.

Pacer S&P SmCp 600 Qul FCF Aristcrts ETF

SPDR S&P SmallCap 600 ESG ETF

ISHRS S-Cap 600/Barra Val

Buy 2 Vanguard index funds to beat the S&P 500 in the next 5 years, according to Wall Street analysts

Arrowhead Pharmaceuticals reported a significant profit surge in Q1 2026, with sales reaching $264.03 million and net income of $30.81 million, a stark contrast to the previous year's $2.5 million in sales. The company was also added to the S&P MidCap 400, indicating a shift in its financial profile. While this move may enhance liquidity and broaden the shareholder base, risks remain tied to clinical trials and partner-dependent revenue. Analysts have varying forecasts for Arrowhead's future revenue, with some projecting a decline, highlighting the uncertainty surrounding its investment narrative.

SPDR S&P Biotech

iShares US Pharma

ArrowHead Pharma

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

VG Health

Is Arrowhead’s Profit Surge and S&P MidCap 400 Move Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

RTXG

UMDD

REGL

TTM Technologies has secured a multi-year supply agreement with Raytheon worth up to $200 million, enhancing its role in defense programs. The company will also join the S&P MidCap 400 index, potentially increasing visibility among institutional investors. While the stock is currently trading 4.9% below analyst targets and is considered 36.5% overvalued, recent momentum shows a 42.32% return over 30 days. Investors should monitor how the contract impacts revenue and whether the high P/E ratio aligns with industry averages.

Leverage Shares 2X Long RTX Daily ETF

Pro UltrPro M-CPro 400

Invesco Aero & Defense ETF

ISHRS Aero & Def

Pro S&P Mid 400 Dvd

SPDR S&P Aerospace & Def

Direxion Mid Cap Bull 3X

ARK Space Exploration & Innovation ETF

TTM Tech

TTM Technologies’ Raytheon Deal And Index Entry Raise Valuation Questions

As global markets face economic uncertainties, investors are focusing on small-cap stocks for potential opportunities. Key indices like the S&P MidCap 400 and Russell 2000 have seen declines. The article highlights ten undiscovered gems with strong fundamentals, including companies like Limin Group, Jiangyin Electrical Alloy, and Beijing Zhidemai Technology, showcasing their financial health and growth potential. These companies exhibit resilience and promising earnings growth, making them attractive options for investors looking to diversify their portfolios in a volatile market.

ProShares UltraShort R2000 ETF

Direxion Small Cap Bear 3X

ProShares Ultra Russell2000 ETF

Undiscovered Gems in Global Markets To Explore This January 2026

KTOS

KTUP

The S&P 400 midcap index has risen by almost 4% so far this year, surpassing the overall market. Among the top performers are Kratos and six other companies leading the rally in S&P Midcap 400 stocks.

Unusual Whales

Kratos Defense & Security

T-REX 2X Long KTOS Daily Target ETF

S&P 400 midcap index up nearly 4% this year, outperforming market; Kratos and 6 others lead the rally.

VG S&P M-Cap 400(IVOO.US)

The SMID Cap Conundrum: Dispersion, Deleveraging And The Selective Opportunity Ahead

Should Vanguard S&P Mid-Cap 400 Index Fund ETF Shares (IVOO) Be on Your Investing Radar?

Global's Top 3 Undervalued Small Caps With Insider Buying To Consider

Does DigitalOcean (DOCN) Entering the S&P MidCap 400 Reframe Its Balance of Growth and Risk?

Solstice Joins S&P MidCap 400 As AI Supply Chain Valuation Story Grows